Oculis Holding AG will present new biomarker analyses from its Phase 2 ACUITY trial of Privosegtor, a potential neuroprotective therapy for optic neuritis, at the 10th Joint ACTRIMS-ECTRIMS Meeting in October 2026. The data focus on plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as indicators of neuroaxonal injury and inflammation, offering insights into the drug's neuroprotective effects. Privosegtor has received Breakthrough Therapy and PRIME designations and is currently being tested in registrational trials for optic neuritis and related conditions. This presentation marks a significant step toward advancing treatment options for optic neuritis, a condition with no approved neuroprotective therapies to prevent vision loss.
The Oculis Holding AG presentation on Phase 2 ACUITY biomarker analyses offers context for readers. For those tracking the health sector, 81 of 150 priced US health stocks rose while 64 fell, as of Oct 20, 2026 13:11 WIB. Notable movers include MESO at USD 12.46 with a -6.17% change, AMWL at USD 12.38 with a +5.99% change, and RLAY at USD 17.06 with a +4.79% change.
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...
Owl Labs has introduced the Meeting Owl 5, a 4K UHD 360° teleconferencing camera designed for seamless hybrid meetings. It features a 20MP sensor, 360° fisheye lens, AI-powered audio with eight microphones, and an 18-foot voice pickup range. The devi...
Pulsar Helium Inc. announced a live "Ask Me Anything" session on October 27, 2026, where CEO Thomas Abraham-James and President Cliff Cain will answer investor questions in real time. The event aims to engage current and potential shareholders direct...
Equinor ASA announced it purchased 389,058 of its own shares on October 15, 2026, at an average price of NOK 429.24 per share as part of its ongoing buy-back program. The program, running from February 13, 2026, to January 15, 2027, aims to buy up to...
Pump.fun (PUMP) token increased by 4.03% in one hour to $0.004565, extending its 24-hour gain to 12.88%. During this period, short positions worth $60,000 were liquidated on Binance, Bybit, and OKX, while no long positions were liquidated. PUMP's mar...
